Nothing Special   »   [go: up one dir, main page]

WO2023189270A1 - Composition de biomatériau - Google Patents

Composition de biomatériau Download PDF

Info

Publication number
WO2023189270A1
WO2023189270A1 PCT/JP2023/008501 JP2023008501W WO2023189270A1 WO 2023189270 A1 WO2023189270 A1 WO 2023189270A1 JP 2023008501 W JP2023008501 W JP 2023008501W WO 2023189270 A1 WO2023189270 A1 WO 2023189270A1
Authority
WO
WIPO (PCT)
Prior art keywords
neutral
mass
lipid
content
composition
Prior art date
Application number
PCT/JP2023/008501
Other languages
English (en)
Japanese (ja)
Inventor
晴貴 冨川
俊英 芳谷
Original Assignee
富士フイルム株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 富士フイルム株式会社 filed Critical 富士フイルム株式会社
Publication of WO2023189270A1 publication Critical patent/WO2023189270A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Definitions

  • the present invention relates to a composition for living organisms.
  • stomatitis may occur when drugs that are likely to cause stomatitis are administered, and during radiation therapy for head and neck cancer (cancer in the head and neck area), stomatitis may occur when the mucous membranes of the mouth are directly exposed to radiation. It originates from The pain of canker sores is so severe that he is unable to take food orally.
  • Symptomatic treatments for stomatitis include patches that are applied directly to the affected area (e.g., Aphthaseal (R) 25 ⁇ g, manufactured by Taisho Toyama Pharmaceutical Co., Ltd.; active ingredient: triamcinolone acetonide), ointments that are applied to the affected area (e.g., dexartine oral ointment, These include Nippon Kayaku Co., Ltd.; active ingredient: dexamethasone); and sprays that are sprayed onto the affected area (for example, Surcoat (R) capsules for external use, 50 ⁇ g; Teijin Pharma Co., Ltd.; active ingredient: beclomethasone propionate).
  • the patch applied to the affected area may come off, or the ointment or spray applied to the affected area may be lost, making it impossible to suppress the pain of stomatitis.
  • a pre-formulation in the form of a low-viscosity mixture (such as a molecular solution) consisting of an amphiphilic component and at least one physiologically active substance optionally included.
  • Preformulations are known that undergo at least one phase transition upon exposure to aqueous fluids, such as body fluids, thereby forming a bioadhesive matrix.
  • Patent Document 1 describes: a) at least one neutral diacyl lipid containing at least 50% glycerol dioleate; b) at least one phospholipid consisting of at least 50% phosphatidylcholine; c) A formulation comprising a low viscosity mixture with 2-30% by weight of at least one biocompatible organic solvent comprising ethanol, The weight ratio of components a:b is 85:15 to 30:70, capable of forming at least one bioadhesive liquid crystalline phase structure upon contact with an aqueous fluid and/or a body surface; Formulations with viscosities of 0.1 to 5000 mPas at 20° C. are described.
  • a biological composition to be applied to a living body contains a physiologically active substance (preparation)
  • various properties are required. Specifically, when a biological composition is applied to an object and brought into contact with water or the like in the atmosphere to form a film, a high film formation rate is required.
  • a liquid crystal film a film exhibiting a liquid crystal phase
  • the film formation rate corresponds to the rate at which the liquid crystal phase is formed. It is also required to have excellent spreadability when applying the biological composition to an object.
  • the formed membrane itself is required to have excellent strength and to have excellent sustained release properties of physiologically active substances from the formed membrane (sustained release properties of the membrane).
  • the present invention provides a biological composition that has excellent spreadability to a target object, a fast film formation rate when brought into contact with water, and excellent strength and sustained release properties of the formed film. That is the issue.
  • [1] Contains a neutral acyl lipid, a phospholipid, an alcohol or polyalkylene oxide having 4 or less carbon atoms, and a physiologically active substance,
  • the content of neutral diacyl lipid in the neutral acyl lipid is more than 0% by mass and not more than 50% by mass
  • a composition for biological use wherein the mass ratio of the content of the neutral acyl lipid to the content of the phospholipid is 54/46 to 1/99.
  • [3] The composition for living organisms according to [1] or [2], wherein the mass ratio is from 49/51 to 36/64.
  • the neutral acyl lipid further contains a neutral monoacyl lipid, The biological composition according to any one of [1] to [4], wherein the content of the neutral monoacyl lipid in the neutral acyl lipid is 40 to 90% by mass.
  • the phospholipid contains phosphatidylcholine,
  • the biological composition according to any one of [1] to [7], wherein the content of the phosphatidylcholine in the phospholipid is at least 50% by mass.
  • the content of the alcohol or polyalkylene oxide having 4 or less carbon atoms is 0.5 to 10 parts by mass based on 100 parts by mass of the total content of the neutral acyl lipid and the phospholipid, [ 1] to [8].
  • Any one of [1] to [9] wherein the water content is 0% by mass or more and 10% by mass or less based on the total amount of the biological composition after removing the physiologically active substance.
  • composition for biological use that has excellent spreadability to a target object, a fast film formation rate when brought into contact with water, and excellent strength and sustained release properties of the formed film. Can be provided.
  • FIG. 1 is a photograph of gelatin gel after sustained release of cyanocobalamin from the biological compositions of Examples 1 to 4 and Comparative Examples 1 to 3 in the sustained release evaluation of the present invention.
  • the meaning of each description in this specification is shown below.
  • the range expressed using “ ⁇ ” shall include both ends of “ ⁇ ”.
  • a range expressed as "A to B" includes A and B.
  • substrate refers to the remainder of the biological composition of the present invention after removing the physiologically active substance.
  • the biological composition of the present invention is a biological composition containing a neutral acyl lipid containing a neutral diacyl lipid, a phospholipid, an alcohol or polyalkylene oxide having 4 or less carbon atoms, and a physiologically active substance. be.
  • a neutral acyl lipid containing a neutral diacyl lipid, a phospholipid, an alcohol or polyalkylene oxide having 4 or less carbon atoms, and a physiologically active substance.
  • Neutral acyl lipid means an electrically neutral acyl lipid. That is, neutral acyl lipids do not contain cationic and anionic moieties. Note that acyl lipid means a lipid containing an acyl group.
  • neutral acyl lipids include neutral diacyl lipids.
  • the neutral acyl lipids can further contain at least one or both of neutral monoacyl lipids and neutral triacyl lipids.
  • the content of neutral diacyl lipid in the neutral acyl lipid is more than 0% by mass (more than 0% by mass) and 50% by mass or less based on the total amount of neutral acyllipid, and From the viewpoint of better effects (particularly spreading properties, film strength, sustained release properties), the amount is preferably 10 to 50% by mass, more preferably 20 to 50% by mass.
  • neutral monoacyl lipid When the neutral acyl lipid further contains a neutral monoacyl lipid, the content of the neutral monoacyl lipid in the neutral acyl lipid increases the effects of the present invention (particularly spreadability, membrane strength, and sustained release properties). From the viewpoint of being superior, it is preferably 40 to 90% by mass, more preferably 40 to 70% by mass, based on the total amount of neutral acyl lipids.
  • the neutral monoacyl lipid preferably contains glycerol monooleate.
  • neutral triacyl lipid In the present invention, the content of neutral triacyl lipids in the neutral acyl lipids is determined from the total amount of neutral acyl lipids in order to improve the effects of the present invention (particularly spreadability, membrane strength, and sustained release properties). On the other hand, it is preferably 0 to 10% by weight, more preferably 1 to 8% by weight.
  • the number of carbon atoms in the acyl group of the neutral acyl lipid is not particularly limited, but is preferably from 6 to 32, more preferably from 16 to 22.
  • the hydrocarbon group other than the carbonyl group of such an acyl group is preferably a saturated or unsaturated chain hydrocarbon group having 5 to 31 carbon atoms, and a saturated or unsaturated chain hydrocarbon group having 15 to 21 carbon atoms.
  • each acyl group may be of the same type or different types.
  • neutral acyl lipids examples include glycerol, diglycerol, sugars (eg, inositol), and lipids obtained by ester bonding polyols such as succinic acid with fatty acids.
  • acylglycerol is preferred, and glycerol oleate is more preferred.
  • Acylglycerols include monoacylglycerols, diacylglycerols, and triacylglycerols.
  • examples of glycerol oleate examples include glycerol monooleate, glycerol dioleate, and glycerol trioleate.
  • monoacylglycerol and glycerol monooleate correspond to one embodiment of the above-mentioned neutral monoacyl lipid
  • diacylglycerol and glycerol dioleate correspond to one embodiment of the above-mentioned neutral diacyl lipid
  • triacylglycerol and triolein Acid glycerol corresponds to one embodiment of the above-mentioned neutral triacyl lipid.
  • the content ratios of neutral monoacyl lipids, neutral diacyl lipids, and neutral triacyl lipids in neutral acyl lipids are obtained by measuring by high performance liquid chromatography (HPLC) method.
  • HPLC high performance liquid chromatography
  • Phospholipid The biological composition of the present invention contains a phospholipid.
  • Phospholipids are not particularly limited as long as they have a phosphate ester structure in their molecular structure, but typical examples include glycerophospholipids that have glycerin as their backbone and sphingophospholipids that have sphingosine as their backbone. Whether the phospholipid is glycerophosphoric acid or sphingophospholipid, it has an acyl group derived from a fatty acid in its molecule.
  • the number of carbon atoms in the acyl group of the phospholipid is not particularly limited, but is preferably 12 to 22, more preferably 16 to 18.
  • the hydrocarbon group other than the carbonyl group of such an acyl group is preferably a saturated or unsaturated chain hydrocarbon group having 11 to 21 carbon atoms, and a saturated or unsaturated chain hydrocarbon group having 15 to 17 carbon atoms. Hydrogen groups are more preferred.
  • each acyl group may be of the same type or different types.
  • a specific example of phospholipid is phosphatidylcholine.
  • phosphatidylcholine examples include PO phosphatidylcholine (phosphatidylcholine having palmitic acid at the 1st position ( ⁇ position), oleic acid at the 2nd position ( ⁇ position), and choline at the 3rd position ( ⁇ position)), DL phosphatidylcholine (phosphatidylcholine having palmitic acid at the 1st position ( ⁇ position), choline at the 3rd position ( ⁇ position)), Examples include linoleic acid at the ⁇ -position), linoleic acid at the 2-position ( ⁇ -position), phosphatidylcholine having choline at the 3-position ( ⁇ -position), and dipalmitoylphosphatidylcholine.
  • PO phosphatidylcholine phosphatidylcholine having palmitic acid at the 1st position ( ⁇ position), oleic acid at the 2nd position ( ⁇ position), and choline at the 3rd position ( ⁇ position)
  • the phospholipid preferably contains an ionic phospholipid from the viewpoint of improving the water absorption rate of the biological composition of the present invention or forming a columnar phase with a large domain size. It is believed that improvement in the water absorption rate, etc. of the biological composition contributes to further improvement in at least one of the film formation rate and the strength of the film. Note that the above-mentioned water absorption rate refers to the rate at which the biological composition of the present invention absorbs water or moisture.
  • ionic phospholipids include phospholipids having a cation part and an anion part in one molecule, and specifically, for example, phosphatidylcholine. Phosphatidylcholine has as a cation moiety N + derived from choline and PO ⁇ derived from phosphoric acid.
  • the content of phosphatidylcholine in the phospholipid is preferably at least 50% by mass based on the total amount of the phospholipid.
  • the upper limit of the content of phosphatidylcholine relative to the total amount of phospholipids is not particularly limited, but may be 99% by mass.
  • the mass ratio of the neutral acyl lipid content to the phospholipid content is 54/46 to 1/99.
  • the above mass ratio is preferably from 54/46 to 30/70, more preferably from 49/51 to 36/64, and even more preferably from 49/51 to 41/59, from the viewpoint of more excellent effects of the present invention.
  • the total content of neutral acyl lipids and phospholipids is preferably 77 to 99.5% by mass based on the total amount of the base material (the remainder after removing the physiologically active substance from the biological composition of the present invention), More preferably 93 to 98% by mass.
  • the biological composition of the present invention contains an alcohol or polyalkylene oxide having 4 or less carbon atoms.
  • the biological composition of the present invention has excellent spreadability by containing alcohol or polyalkylene oxide having 4 or less carbon atoms.
  • the alcohol having 4 or less carbon atoms is not particularly limited as long as it is a biocompatible compound.
  • Alcohols having 4 or less carbon atoms can function as a solvent.
  • polyalkylene oxide can function as a solvent. The same applies to polyalkylene oxide.
  • Alcohol with carbon number of 4 or less is a compound in which a hydroxyl group is bonded to an aliphatic hydrocarbon group having 3 or less carbon atoms.
  • the number of hydroxy groups in one molecule of the alcohol having 4 or less carbon atoms is preferably 1 or 2.
  • Examples of the alcohol having 4 or less carbon atoms include monoalcohols such as ethanol; dialcohols such as propylene glycol and 1,3-butylene glycol.
  • Polyalkylene oxide is a polymer having oxyalkylene groups as repeating units. The terminal end of the polyalkylene oxide may form a hydroxy group. The polyalkylene oxide may have one or more hydroxy groups per molecule. Examples of the polyalkylene oxide include polyoxyethylene polyol, polyoxypropylene polyol, and polyoxyethylene oxypropylene polyol.
  • the content of alcohol or polyalkylene oxide having 4 or less carbon atoms is preferably 0.5 to 10 parts by mass, and 2.0 to 8.0 parts by mass, based on 100 parts by mass of the total content of neutral acyl lipids and phospholipids. Parts by mass are more preferred.
  • the biological composition of the present invention contains an alcohol having 4 or less carbon atoms and a polyalkylene oxide
  • the total content of the alcohol having 4 or less carbon atoms and the polyalkylene oxide is the total content of neutral acyl lipids and phospholipids.
  • the amount can be 1.0 to 20 parts by mass per 100 parts by mass.
  • the biological composition of the present invention contains a physiologically active substance.
  • the physiologically active substance may be any substance (active ingredient) to be administered to a living body.
  • Physiologically active substances are not lipids.
  • the physiologically active substance may be an organic compound or an inorganic compound.
  • the physiologically active substance may be water-soluble or fat-soluble (lipophilic, water-insoluble, or poorly water-soluble).
  • Physiologically active substances may include, but are not limited to, proteins, peptides, amino acids, nucleic acids, vitamins, hormones, enzymes, minerals, and the like.
  • Physiologically active substances include, for example, anticancer drugs, immunosuppressants, analgesics (e.g., non-opioid analgesics, opioid analgesics such as morphine), anti-inflammatory agents, antiallergic agents (such as tranilast), and steroid drugs (triamcinolone, etc.).
  • analgesics e.g., non-opioid analgesics, opioid analgesics such as morphine
  • anti-inflammatory agents e.g., anti-inflammatory agents, antiallergic agents (such as tranilast), and steroid drugs (triamcinolone, etc.).
  • antiobesity drugs antidiabetic drugs, antibiotics, antifungals, antiviral drugs, vasodilators, anesthetics, smoking cessation aids (nicotine, etc.), antipsychotics, antihypertensive drugs, cardiotonic drugs, beta Blockers, anti-anemic agents, anti-hyperlipidemic agents, bronchodilators, anti-dementia drugs, therapeutic agents for brain and central nervous system diseases such as Alzheimer's disease, Parkinson's disease, cerebrovascular disorders, or brain tumors, chronic obstructive pulmonary disease
  • the drug may be a drug for treating COPD, a drug for treating glaucoma, a drug for treating cataracts, a drug for treating age-related macular degeneration, a drug for treating overactive bladder, a drug for treating attention deficit/hyperactivity disorder, a hormonal agent, a vaccine, etc. , but not limited to.
  • the content of the physiologically active substance is not limited to the following, it is typically 0.0001% by mass or more, for example, 0.0001 to 10% by mass, based on the total amount of the biological composition of the present invention. , 0.0005 to 5% by mass, 0.0005 to 1% by mass, 0.001 to 5% by mass, 0.001 to 1% by mass, 0.001 to 0.1% by mass, 0.001 to 0.05 mass%, 0.001 to 0.01 mass%, 0.01 to 5 mass%, 0.01 to 1 mass%, 0.01 to 0.1 mass%, 0.05 to 1 mass%, or 0. It may be 1 to 0.5% by weight.
  • the content of the base material is not limited to the following, the content of the base material can be the amount obtained by removing the content of the physiologically active substance from the total amount of the biological composition of the present invention.
  • the biological composition of the present invention can further contain a quaternary ammonium salt (excluding phosphatidylcholine) and water.
  • a quaternary ammonium salt is an ionic compound consisting of a positively charged polyatomic ion (quaternary ammonium cation) represented by the molecular formula NR 4 + and an anion.
  • NR 4 + R each independently represents an alkyl group or an aryl group, and a plurality of R's may be the same or different from each other.
  • Anions are not particularly limited.
  • quaternary ammonium salts include dioleoyloxytrimethylammoniumpropane chloride (DOTAP, N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride), Octadecenyltrimethylammoniumpropane chloride (DOTMA, N-[1-(2,3-dioleyloxy)propyl)]-N,N,N-trimethylammonium chloride), didecyldimethylammonium chloride, didecyldimethylammonium Bromide, dilauryldimethylammonium chloride, dicetyldimethylammonium chloride, dicetyldimethylammonium bromide, distearyldimethylammonium chloride, distearyldimethylammonium bromide, dioleyldimethylammonium chloride, dibehenyldimethylammonium chloride, dibehenyl
  • the biological composition of the present invention may or may not contain water.
  • the water content is preferably 0% by mass or more and 10% by mass or less, more preferably 0% by mass, based on the total amount of the biological composition of the present invention after removing the physiologically active substance (substrate).
  • the biological composition of the present invention can be considered to be water-free.
  • carboxyvinyl polymers are vinyl polymers having carboxy groups and salts thereof.
  • carboxyvinyl polymers include polymers having repeating units derived from acrylic acid and/or methacrylic acid as the main chain. Carboxyvinyl polymers may be crosslinked.
  • carboxyvinyl polymers reference can be made to WO 2020/059543. Note that the embodiment including the carboxyvinyl polymer may or may not further include the amphiphilic block polymer described below.
  • the biomedical composition of the present invention also includes an amphiphilic block polymer consisting of a hydrophilic segment and a hydrophobic segment, in which the difference in ClogP value between the hydrophilic segment and the hydrophobic segment is greater than 1.00. It is preferable to exclude aspects. That is, it is preferable that the biological composition of the present invention does not contain the above-mentioned amphiphilic block polymer.
  • the amphiphilic block polymer described in International Publication No. 2020/202926 "consists of a hydrophilic segment and a hydrophobic segment, and the difference in ClogP value between the hydrophilic segment and the hydrophobic segment is 1. 00, amphiphilic block polymer". Note that the embodiment including the amphiphilic block polymer may or may not further include the carboxyvinyl polymer.
  • a neutral acyl lipid, a phospholipid, an alcohol or polyalkylene oxide having 4 or less carbon atoms, and a physiologically active substance may be used as necessary.
  • a method of mixing the above-mentioned other components can be mentioned.
  • the content of neutral diacyl lipids may be more than 0% by mass and 50% by mass or less based on the total amount of neutral acyllipids, and the content of neutral acyllipids should be less than 50% by mass relative to the content of phospholipids.
  • the mass ratio may be from 54/46 to 1/99.
  • the mixing method is not particularly limited, and conventionally known methods can be used.
  • the biological composition of the present invention can form a liquid crystal phase when it comes into contact with water.
  • the biological composition of the present invention forms a film by forming a liquid crystal phase.
  • the biological composition of the present invention can rapidly form a liquid crystal phase in a short period of time even when it comes into contact with a small amount of water, such as water (humidity) in the atmosphere.
  • the thickness of the liquid crystal phase (film) formed by the biological composition of the present invention is not particularly limited, but may be, for example, 0.1 ⁇ m to 1 mm.
  • the biological composition of the present invention can adhere more strongly to objects when it comes into contact with water.
  • water examples of water that comes into contact with the biological composition of the present invention include water (humidity) in the atmosphere, water (humidity) in exhaled breath, pure water, and water contained in aqueous fluids other than water.
  • aqueous fluids other than water examples include saliva, tissue fluid, blood, and lymph fluid.
  • the amount of water brought into contact with the biological composition of the present invention is not particularly limited, but 1000% by mass or less of the total weight of the biological composition of the present invention It is preferably 500% by mass or less, and more preferably 500% by mass or less.
  • the lower limit of the amount of water, based on the total mass of the biological composition of the present invention, which is used when contacting with the biological composition of the present invention, is not particularly limited, but may be, for example, more than 1% by mass.
  • the temperature at which the biological composition of the present invention is brought into contact with water is not particularly limited, but is preferably 20 to 40°C, more preferably 35 to 40°C.
  • the liquid crystal phase that can be formed when the biological composition of the present invention comes into contact with water is not particularly limited, but includes reverse hexagonal columnar (H2) phase, hexagonal columnar (H1) phase, lamellar (La) phase, and sponge (V2) phase. It is often selected from the group consisting of a bicontinuous cubic (L3) phase, a bicontinuous cubic (L3) phase, and a mixed state of two or more of these.
  • the liquid crystal phase preferably has a reverse hexagonal columnar phase (W/O hexagonal columnar phase) or a hexagonal columnar (H1) phase (O/W hexagonal columnar phase).
  • the biological composition of the present invention preferably forms a reverse hexagonal columnar (H2) phase by absorbing water or moisture, and more preferably forms a reverse hexagonal columnar (H2) phase by absorbing moisture.
  • Moisture absorption refers to the absorption of moisture. Examples of moisture include water in the atmosphere and water in exhaled breath. As used herein, water absorption refers to absorbing water (excluding moisture). Examples of water (excluding moisture) include pure water and the above-mentioned aqueous fluids other than water.
  • the biological composition of the present invention means a material that can be used for living organisms. Assist or repair parts of living organisms that no longer function as intended due to injury or disease (e.g. objects such as skin and mucous membranes; the same shall apply hereinafter for "parts"), and parts whose functions have deteriorated.
  • the biological composition of the present invention can be used for the purpose of Since the composition for biological use of the present invention contains a physiologically active substance, it can function as a pharmaceutical preparation. By applying the biological composition of the present invention to the biological surface, a physiologically active substance is released from the biological composition of the present invention to the biological surface, and can be absorbed into the body through the skin or mucous membrane.
  • the biological composition of the present invention can be preferably used for transdermal absorption or mucosal absorption (especially for oral mucosal absorption).
  • a method for using the biological composition of the present invention includes, for example, placing the biological composition of the present invention on a part having the above-mentioned symptoms, and then adding the biological composition of the present invention with water.
  • An example is a method of contacting.
  • the biological composition of the present invention When using the biological composition of the present invention on the skin, for example, the biological composition of the present invention is applied onto the skin in the air, and the biological composition of the present invention is added with water or water as necessary. What is necessary is just to add a solution containing.
  • the biological composition of the present invention on the skin can undergo a liquid crystal phase by contacting, for example, with water in the atmosphere, water atomized by a spray, the above-mentioned aqueous fluids, and exudates from the skin. can be formed.
  • the biological composition of the present invention When using the biological composition of the present invention on mucous membranes, the biological composition of the present invention is placed on the mucous membrane, and water or a solution containing water is added to the biological composition of the present invention as necessary. do it.
  • the biological composition of the present invention on mucous membranes can be applied, for example, by contact with any of the following: water in the atmosphere, water in exhaled breath, water atomized by a spray, the above-mentioned aqueous fluids, and water from drinking or drinking. , a liquid crystal phase can be formed.
  • the biological composition of the present invention when applying the biological composition of the present invention to the oral mucosa, if the biological composition of the present invention is attached (applied) to the oral mucosa, water in the atmosphere, water in exhaled breath, and saliva can be absorbed. Since a liquid crystal phase is formed upon contact with any of the moisture contained therein, handling is easy. Furthermore, if the amount of saliva is small, water may be supplied by spraying water or artificial saliva after adhering the biological composition of the present invention to the oral mucosa.
  • phase transition After absorbing moisture, the biological composition of the present invention may undergo a phase transition in its liquid crystal phase by further absorbing water. It is preferable that the liquid crystal phase of the biological composition of the present invention undergoes a phase transition, thereby improving the effects of the present invention (particularly sustained release properties).
  • the phase transition include phase transition from a reverse hexagonal columnar (H2) phase to a hexagonal columnar (H1) phase.
  • a liquid crystal phase for example, a reverse hexagonal columnar (H2) phase
  • moisture such as water sprayed or artificial saliva, aqueous fluids, exudates from the skin, and water from eating and drinking.
  • a liquid crystal phase undergoes a phase transition to another liquid crystal phase (for example, a hexagonal columnar (H1) phase).
  • the biological composition of the present invention contains a water-soluble physiologically active substance as a physiologically active substance, and the biological composition of the present invention changes from a W/O reverse hexagonal columnar (H2) phase to an O/W hexagonal columnar (H1) phase.
  • the physiologically active substance is accommodated inside each column (W side of W/O) forming a reverse hexagonal columnar (H2) phase, and due to the phase transition, the physiologically active substance is transferred to the column. Since it can be released from inside the body, it is more preferable from the viewpoint of the effects of the present invention (particularly sustained release).
  • Plastibase (R) (manufactured by Taisho Pharmaceutical Co., Ltd.) was used as the base material.
  • Plastibase® is a hydrocarbon gel ointment base containing 95% liquid paraffin and 5% polyethylene resin as a gelling agent. Plastibase® is free of neutral acyl lipids and phospholipids.
  • macrogol ointment (manufactured by Yoshida Pharmaceutical Co., Ltd.) was used as the base material.
  • Macrogol ointment is an ointment containing polyethylene glycol 400 and polyethylene glycol 4000. Macrogol ointment is free of neutral acyl lipids and phospholipids.
  • Cyanocobalamin manufactured by Fujifilm Wako Pure Chemical Industries, Ltd. was dispersed in each of the above base materials in a mortar to prepare each biological composition (sample).
  • the content of cyanocobalamin was 0.1% by mass based on the total amount of each biological composition.
  • each biological composition prepared as above was applied in the form of a square measuring 4.5 cm long and 1 cm wide, and kept at room temperature (25°C) and 50% relative humidity for 24 hours Let it stand for a while. After 24 hours, the biological composition was removed from the top of the gelatin gel, and the area of the gelatin gel from which the biological composition was removed (the size of the gelatin gel was 4.5 cm long, 1 cm wide, and 7 mm thick) was measured using a measurement cell. I put it in. Place the measurement cell on the UV-VIS absorption measuring device (Spectrophotometer "V-670" manufactured by JASCO Corporation) so that the light hits the side of the gelatin gel (4.5 cm long and 7 mm thick). I set it.
  • UV-VIS absorption measuring device Spectrophotometer "V-670” manufactured by JASCO Corporation
  • Spectroscopic measurements were performed to measure the absorbance (abs) at 550 nm, and the sustained release properties of the membrane were evaluated based on the measured absorbance based on the following criteria.
  • -Evaluation Criteria When the absorbance (abs) at 550 nm measured as described above was 0.80 or more, it was evaluated that the sustained release property of the obtained membrane was particularly excellent, and this was indicated as "S”. When the absorbance was 0.10 or more and less than 0.80, the sustained release property of the obtained membrane was evaluated to be very excellent, and this was designated as "A”. When the absorbance was 0.02 or more and less than 0.10, the sustained release properties of the obtained membrane were evaluated to be somewhat excellent, and this was designated as "B”.
  • the ratio of the scattering vector length (q/nm ⁇ 1 ) was measured to identify the liquid crystal structure.
  • the ratio of the scattering vector lengths of the respective peaks was 1: ⁇ 3: ⁇ 4
  • the ratio of the scattering vector lengths of the three peaks of 1: ⁇ 3: ⁇ 4 is unique to the reverse hexagonal columnar phase. -Evaluation results When the liquid crystal phase was a reverse hexagonal columnar phase, this was indicated as "H2". When the liquid crystal phase was not a reverse hexagonal columnar phase, this was indicated as "not H2".
  • Neutral acyl lipid 2 The mass ratio of neutral monoacyl lipid, neutral diacyl lipid, and neutral triacyl lipid is 95:5:0, and the neutral monoacyl lipid contains glycerol monooleate. Contains neutral acyl lipids.
  • GLYMOIST-MO manufactured by NOF Corporation
  • Neutral acyl lipid 3 A neutral acyl lipid containing a neutral monoacyl lipid, a neutral diacyl lipid, and a neutral triacyl lipid at a mass ratio of 3:78:19. Manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.
  • Phospholipid Phosphatidylcholine.
  • Lipoid P100 manufactured by Lipoid.
  • the content of phosphatidylcholine is 97.3% by mass in the above product.
  • Comparative Example 5 which did not contain either the predetermined alcohol or polyalkylene oxide but instead contained oleyl alcohol, had low spreadability to the object. Comparative Examples 7 and 8, which did not contain neutral acyl lipids and phospholipids, did not form a liquid crystal phase (film). In Comparative Example 7, the sustained release properties of the membrane were even worse. Comparative Example 8 had even lower spreadability.
  • the composition for biological use of the present invention has excellent spreadability to a target object, a fast film formation rate when it is brought into contact with water to form a film, and excellent film strength and sustained release properties.
  • the mass ratio of the neutral acyl lipid content to the phospholipid content is 49/51 to 36/64 (more preferably 49/51 to 41/64) 59)
  • the effect is more excellent when the content of neutral monoacyl lipid in the neutral acyl lipid is 40 to 90% by mass.
  • FIG. 1 is a photograph of gelatin gel after sustained release of cyanocobalamin from the biological compositions of Examples 1 to 4 and Comparative Examples 1 to 3 in the sustained release evaluation of the present invention.
  • a gelatin gel 2 is housed in a measurement cell 1 (the size of the gelatin gel 2 is 4.5 cm long, 1 cm wide, and 7 mm thick).
  • the method for producing the measurement cell 1 containing the gelatin gel 2 is the same as the sustained release evaluation method described above.
  • the photograph in FIG. 1 is a side view (4.5 cm long and 7 mm thick) of the gelatin gel 2 of each Example and Comparative Example.
  • gelatin gel 2 of Comparative Example 1 was almost colorless and transparent as a whole, and almost no coloring (red) due to cyanocobalamin was observed.
  • Comparative Examples 2 and 3 On the other hand, in Examples 1 to 4, a colored portion 4 was generated from the surface 3 to the inside of the gelatin gel 2 (the colored portion 4 was colored red). Colored area 4 indicates that cyanocobalamin was sustainedly released from the biological compositions of Examples 1 to 4, and that the sustainedly released cyanocobalamin penetrated into the gelatin gel.
  • Example 1 the color of colored portion 4 of Example 3 was the darkest.
  • the portions other than the colored portion 4 were almost colorless and transparent.
  • the membrane formed from the biological composition of the present invention had excellent sustained release properties.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition de biomatériau ayant une excellente aptitude à l'étalement sur un objet, un taux de formation de film élevé lorsqu'un film est formé en étant mis en contact avec de l'eau, et une excellente résistance de film ainsi que d'excellentes propriétés de libération prolongée. La présente invention concerne une composition de biomatériau comprenant un lipide acyle neutre, un phospholipide, un alcool ou un oxyde de polyalkylène ayant au maximum 4 atomes de carbone, et une substance biologiquement active. Selon l'invention : la teneur en lipide diacyle neutre dans le lipide acyle neutre va de 0 à 50 % en masse (à l'exclusion de 0) ; et le rapport en masse de la teneur en lipide acyle neutre à la teneur en phospholipide va de 54/46 à 1/99.
PCT/JP2023/008501 2022-03-28 2023-03-07 Composition de biomatériau WO2023189270A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022051370 2022-03-28
JP2022-051370 2022-03-28

Publications (1)

Publication Number Publication Date
WO2023189270A1 true WO2023189270A1 (fr) 2023-10-05

Family

ID=88201340

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2023/008501 WO2023189270A1 (fr) 2022-03-28 2023-03-07 Composition de biomatériau

Country Status (1)

Country Link
WO (1) WO2023189270A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11513393A (ja) * 1995-10-12 1999-11-16 ジーエス ディベロップメント エービー 皮膚又は粘膜表面へのもしくは介する活性物質の投与用医薬組成物
JP2008509120A (ja) * 2004-08-04 2008-03-27 カムルス エービー 非層状分散を生じる組成物
JP2018517745A (ja) * 2015-06-16 2018-07-05 サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッドＳｕｎ Ｐｈａｒｍａ Ａｄｖａｎｃｅｄ Ｒｅｓｅａｒｃｈ Ｃｏｍｐａｎｙ Ｌｉｍｉｔｅｄ 長時間作用リラグルチド組成物
JP2019510048A (ja) * 2016-03-31 2019-04-11 サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッドＳｕｎ Ｐｈａｒｍａ Ａｄｖａｎｃｅｄ Ｒｅｓｅａｒｃｈ Ｃｏｍｐａｎｙ Ｌｉｍｉｔｅｄ 週１回又は隔週１回の投与に適したリラグルチドの粘弾性ゲル
WO2020059543A1 (fr) * 2018-09-20 2020-03-26 富士フイルム株式会社 Biomatériau
WO2020202926A1 (fr) * 2019-03-29 2020-10-08 富士フイルム株式会社 Matériau biologique

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11513393A (ja) * 1995-10-12 1999-11-16 ジーエス ディベロップメント エービー 皮膚又は粘膜表面へのもしくは介する活性物質の投与用医薬組成物
JP2008509120A (ja) * 2004-08-04 2008-03-27 カムルス エービー 非層状分散を生じる組成物
JP2018517745A (ja) * 2015-06-16 2018-07-05 サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッドＳｕｎ Ｐｈａｒｍａ Ａｄｖａｎｃｅｄ Ｒｅｓｅａｒｃｈ Ｃｏｍｐａｎｙ Ｌｉｍｉｔｅｄ 長時間作用リラグルチド組成物
JP2019510048A (ja) * 2016-03-31 2019-04-11 サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッドＳｕｎ Ｐｈａｒｍａ Ａｄｖａｎｃｅｄ Ｒｅｓｅａｒｃｈ Ｃｏｍｐａｎｙ Ｌｉｍｉｔｅｄ 週１回又は隔週１回の投与に適したリラグルチドの粘弾性ゲル
WO2020059543A1 (fr) * 2018-09-20 2020-03-26 富士フイルム株式会社 Biomatériau
WO2020202926A1 (fr) * 2019-03-29 2020-10-08 富士フイルム株式会社 Matériau biologique

Similar Documents

Publication Publication Date Title
JP7250689B2 (ja) 活性化合物のための局所送達系
El-Refaie et al. Novel self-assembled, gel-core hyaluosomes for non-invasive management of osteoarthritis: in-vitro optimization, ex-vivo and in-vivo permeation
ES2211984T3 (es) Preparado para el transporte de una sustancia activa a traves de barreras.
US20210196826A1 (en) Biomaterial
JP7201795B2 (ja) 生体材料
ITMI20090350A1 (it) Glicerosomi e loro impiego in preparazioni farmaceutiche e cosmetiche per uso topico
D Mishra et al. Formulation and optimization of ethosomes for transdermal delivery of ropinirole hydrochloride
CN118615249A (zh) 用于控制曲前列环素的释放的医药组合物
WO2023189270A1 (fr) Composition de biomatériau
WO2023189273A1 (fr) Composition biologique
JP6751829B2 (ja) 液状外用剤
CN110898006A (zh) 一种载药微米介孔硅、其透皮制剂及制备方法和应用
CN115475152A (zh) 氟比洛芬的外用制剂及其制备方法
Hardia et al. Formulation and In Vitro and Skin Permeability Evaluation of Dexamethasone Loaded Niosomal Gel
JPH01165523A (ja) ネドクロミルナトリウム組成物およびその調製方法
Begum et al. Formulation Development and In-Vitro Evaluation of Transferosomal Gel of Mometasone Furoate
Shah et al. Formulation, Development and Characterization of Liposome-based Gel of Eberconazole Nitrate for Topical Delivery.
WO2024219344A1 (fr) Composition pour corps vivant
PATEL et al. Local delivery of Tacrolimus from Liposomal Gel for treatment of Atopic Dermatitis.
Ravi et al. Enhancement Of Bioavailability Dapsone By Transdermal Drug Delivery System-Formulation And Evaluation
WO2020050423A1 (fr) Préparation externe comprenant un lipide formant des cristaux liquides non lamellaires
Khan et al. Formulation and Evaluation of Ethosomal Gel of Ciprofloxacin for Bacterial Infections
Tomar et al. Formulation and evaluation of topical gel containing azithromycin and prednisolone vesicles for treating psoriasis
Suriaprabha et al. Effect of carbopol gel in stable liposomes and their enhanced antipyretic effect
Patch Indian Journal of Novel Drug Delivery

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23779297

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2024511590

Country of ref document: JP

Kind code of ref document: A